The origins of the company date back to 1976. Since then, a story of international growth, global presence and strong partnerships has been nurtured, all focused on improving patients’ quality of life. Learn more about us on our renewed corporate website: https://lnkd.in/gVvPYgVh #companyprofile #pharma
关于我们
Welcome to Helsinn’s LinkedIn page. This account shall only be used to share (*) news concerning Helsinn. We would like to emphasize that due to the highly regulated nature of the pharma industry, we cannot engage with you online in any discussions concerning our or other companies’ products and/or services, and/or treatment options. It is best to hold such discussions and to seek guidance privately from your healthcare professional Helsinn is a global pharmaceutical company that builds, manufactures, launches, and commercializes products to improve the quality of life for patients with cancer and chronic disease, with a focus on supportive care, oncology and dermato-oncology. Helsinn, headquartered in Lugano, Switzerland, has direct commercial operations in the U.S. and an extensive network of long-standing trusted partners enabling a commercial presence in more than 90 countries. Established in 1976, Helsinn is a third-generation family-owned company with broad pharmaceutical and technical expertise. Helsinn is proud of its history of operating with great integrity, passion and quality. The company is committed to continuously striving for innovation for its patients and embracing sustainable growth as a core element of its strategic vision. If you are interested in joining Helsinn or one of our affiliates, please visit helsinn.com. Applications should only be submitted via the appropriate country portal under “Working for Helsinn”. Any other sources of communications are unauthorized, and we discourage candidates from replying to suspect employment offers received through unofficial channels. If you are experiencing problems or have questions, please contact: Switzerland: [email protected], U.S.: [email protected], Ireland: [email protected]. [These emails are NOT an application channel: CVs and sensitive information sent inappropriately to the above emails will NOT be considered or processed, and will be DELETED]
- 网站
-
http://www.helsinn.com
Helsinn Group的外部链接
- 所属行业
- 制药业
- 规模
- 201-500 人
- 总部
- Lugano/Pazzallo，Ticino
- 类型
- 私人持股
- 创立
- 1976
地点
Helsinn Group员工
动态
-
Dr. Melanie Rolli shares her thoughts on what Helsinn has achieved in the first half of the year. #ceotalks
Today, I am excited to share with you some important achievements at the Helsinn Group in the first half of 2024. - As partner of choice, we have successfully renewed distribution and licensing agreements with some of our long-standing partners. - In the US, we launched AKYNZEO® (fosnetupitant/palonosetron) in a ready-to-use vial, providing new preparation and administration features. - Commercial supplies exceeded expectations and were delivered on time confirming the high performance track record of our manufacturing site HBP - For the fourth consecutive year we achieved carbon neutrality, we have continued our efforts in ESG practices completing the sustainability report for 2023 full year, and we have actively promoted local CSR initiatives. Our global team delivered these results with expertise, commitment and passion: I am proud of our achievements and confident in our ongoing transformational journey. #business #pharma
-
-
Today marks #EarthOvershootDay – the day when humanity's demand for ecological resources exceeds what the Earth can regenerate in one year. At Helsinn, we recognize the interconnectedness of human health and planetary well-being. As a carbon neutral company, we are deeply committed to minimizing our environmental footprint and contributing to a sustainable future. But our responsibility extends beyond our operations. We invite you to join us in reflecting on Earth Overshoot Day and taking steps to #MoveTheDate. Let's embrace sustainable practices, advocate for change, and work together to protect the resources that sustain us all. Together, we can create a healthier planet for ourselves and for future generations. Click here to find out more about our commitment to sustainability: https://lnkd.in/dhfYtigK
-
-
Nausea and vomiting (NV) are common side effects of anticancer treatment, assessed in acute (first 24 hours), delayed (days 2-5), and long-delayed (beyond day 5) phases. Emerging data on certain antibody-drug conjugates (ADCs) suggest NV may persist well into the long-delayed phase, impacting patients’ quality of life and treatment continuity. #seeCINVbetter #supportivecare #ADCs
-
Evolving data on new antibody-drug conjugates (ADCs) suggests that some may cause nausea and vomiting lasting more than 5 days (referred to as “long-delayed CINV”). Administering guideline-recommended antiemetic prophylaxis is critical, especially considering the extended treatment duration for many patients. As uncontrolled CINV significantly increases the risk for CINV in subsequent cycles, appropriate upfront antiemetics when initiating ADCs are essential to optimize patient outcomes. #seeCINVbetter #supportivecare #ADCs
-
We are pleased to announce that AKYNZEO® injection (fosnetupitant/palonosetron) is now available in the US in a ready-to-use vial. Dr. Melanie Rolli expresses her insights on this significant milestone. To find out more, read the full announcement here: https://lnkd.in/dnapPdkW #supportivecare
-
-
Our technical organization orchestrates a balanced mix of internal and external capabilities also for manufacturing and supply chain. At our state-of-the-art manufacturing facility in Ireland, we manufacture commercial solid and semisolid dosage forms and handle high-potency drugs. Analytical testing and QP release are run on site, as is the management of the global supply chain that reaches patients all around the globe. Learn more about our journey to in-house product manufacturing and supply: https://lnkd.in/ekCtvEJp #manufacturing
-
-
This is the future vision for Helsinn Group as explained by our #CEO Dr. Melanie Rolli. #transformation
For the future, we envision a world where patients with cancer and chronic diseases, their families and care givers, and healthcare professionals have seamless access to our integrated medication and care solutions. Read more about how we are transforming and what is driving this #transformation. https://lnkd.in/eA3f7sdq
-
-
Today, we have the opportunity to be on the ground and connect with the healthcare community at the MASCC Annual Meeting in Paris. We have the chance to explore the latest advances in #supportivecare to reinforce our commitment to improving patients' quality of life. #MASCC24
-
-
Helsinn is committed to raising awareness of the importance of antiemetic guidelines. In synch with the #MASCC24 annual meeting, Helsinn reminds HCPs that MASCC/ESMO released new antiemetic guidelines. Key practice changing updates include recommended use of a triple combination of a NK1 receptor antagonist (RA), 5-HT3 RA and steroids prophylactically in situations where emetogenic potential is now considered at the high end of the moderate category (eg, for patients receiving carboplatin (AUC ≥ 5), for women <50 receiving oxaliplatin, for patients receiving ADCs such as trastuzumab-deruxtecan and sacituzumab-govitecan). #supportivecare #antiemetics #CINV
-